Sheri Nixdorf
Sheri Nixdorf
Research Associate/Associate Lecturer, University of New South Wales
Verified email at
Cited by
Cited by
Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines
F Jacob, R Guertler, S Naim, S Nixdorf, A Fedier, NF Hacker, ...
PloS one 8 (3), e59180, 2013
Emerging roles for phospholipase A2 enzymes in cancer
KF Scott, M Sajinovic, J Hein, S Nixdorf, P Galettis, W Liauw, P de Souza, ...
Biochimie 92 (6), 601-610, 2010
Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status
M Anugraham, F Jacob, S Nixdorf, AV Everest-Dass, ...
Molecular & Cellular Proteomics 13 (9), 2213-2232, 2014
The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells
CE Ford, E Jary, SSQ Ma, S Nixdorf, VA Heinzelmann-Schwarz, RL Ward
PloS one 8 (1), e54362, 2013
Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology
RD Loberg, CK Neeley, LL Adam-Day, Y Fridman, LN St John, S Nixdorf, ...
International journal of oncology 26 (6), 1699-1705, 2005
Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines
S Nixdorf, MO Grimm, R Loberg, A Marreiros, PJ Russell, KJ Pienta, ...
Cancer letters 215 (2), 209-220, 2004
The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer
CE Ford, G Punnia-Moorthy, CE Henry, E Llamosas, S Nixdorf, J Olivier, ...
Gynecologic oncology 134 (2), 338-345, 2014
Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients
F Jacob, K Ukegjini, S Nixdorf, CE Ford, J Olivier, R Caduff, JP Scurry, ...
PloS one 7 (2), e31885, 2012
A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker
VA Heinzelmann-Schwarz, S Nixdorf, M Valadan, M Diczbalis, J Olivier, ...
International journal of molecular medicine 33 (4), 784-794, 2014
Reliable in vitro studies require appropriate ovarian cancer cell lines
F Jacob, S Nixdorf, NF Hacker, VA Heinzelmann-Schwarz
Journal of ovarian research 7, 1-10, 2014
Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells
F Jacob, MP Hitchins, A Fedier, K Brennan, S Nixdorf, NF Hacker, R Ward, ...
BMC molecular biology 15, 1-13, 2014
Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
TR Jue, K Nozue, AJ Lester, S Joshi, LBW Schroder, SP Whittaker, ...
Journal of translational medicine 15, 1-8, 2017
Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma
M Anugraham, F Jacob, AV Everest‐Dass, A Schoetzau, S Nixdorf, ...
Molecular oncology 11 (11), 1595-1615, 2017
Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells
S Decollogne, S Joshi, SA Chung, PP Luk, RX Yeo, S Nixdorf, A Fedier, ...
Gynecologic oncology 138 (2), 363-371, 2015
The role of TP53 gain-of-function mutation in multifocal glioblastoma
LR Olafson, M Gunawardena, S Nixdorf, KL McDonald, RW Rapkins
Journal of Neuro-oncology 147, 37-47, 2020
Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
A Lester, R Rapkins, S Nixdorf, M Khasraw, K McDonald
Clinical and Translational Oncology 19, 273-278, 2017
Elevated levels of prostate‐specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis
S Downing, C Bumak, S Nixdorf, K Ow, P Russell, P Jackson
Molecular Carcinogenesis: Published in cooperation with the University of …, 2003
Advances in lipid-based nanocarriers for breast cancer metastasis treatment
I Joun, S Nixdorf, W Deng
Frontiers in Medical Technology 4, 893056, 2022
Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: a subset analysis of the CABARET trial
LR Olafson, AH Siddell, KM Field, M Byrnes, RW Rapkins, B Ng, S Nixdorf, ...
Journal of Clinical Neuroscience 70, 157-163, 2019
P-1 Antigen is Present on the Serous Ovarian Cancer Cell Line, IGROV1, Correlating with A4GALT Overexpression and Altered Cell Behaviour
F Jacob, BWC Tse, R Guertler, S Nixdorf, NV Bovin, NF Hacker, ...
Glycobiology 21 (11), 1519-1520, 2011
The system can't perform the operation now. Try again later.
Articles 1–20